Apellis Pharmaceuticals' Partner Sobi Gains EU Approval for Aspaveli in Rare Kidney Diseases

MT Newswires Live01-16

Apellis Pharmaceuticals (APLS) partner Sobi said Friday that the European Commission approved Aspaveli (pegcetacoplan) for adults and adolescents aged 12 to 17 with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN).

The therapy is used with a renin-angiotensin system (RAS) inhibitor unless it is not tolerated or contraindicated, Sobi said.

Aspaveli is a targeted C3/C3b inhibitor that regulates excessive complement activation, a key driver of these rare kidney diseases. C3G and IC-MPGN affect about 8,000 patients in Europe. Over half progress to kidney failure within five to 10 years, the company said.

Sobi and Apellis Pharmaceuticals hold global co-development rights, the release said.

Apellis shares were 1.7% higher in premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603199663?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 21:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603199663","market":"hk","top_or_hot":-1,"title":"Apellis Pharmaceuticals' Partner Sobi Gains EU Approval for Aspaveli in Rare Kidney Diseases","media":"MT Newswires Live","content":"<html><body><p> Apellis Pharmaceuticals (APLS) partner Sobi said Friday that the European Commission approved Aspaveli (pegcetacoplan) for adults and adolescents aged 12 to 17 with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN).</p><p>The therapy is used with a renin-angiotensin system (RAS) inhibitor unless it is not tolerated or contraindicated, Sobi said.</p><p>Aspaveli is a targeted C3/C3b inhibitor that regulates excessive complement activation, a key driver of these rare kidney diseases. C3G and IC-MPGN affect about 8,000 patients in Europe. Over half progress to kidney failure within five to 10 years, the company said.</p><p>Sobi and Apellis Pharmaceuticals hold global co-development rights, the release said.</p><p>Apellis shares were 1.7% higher in premarket trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apellis Pharmaceuticals' Partner Sobi Gains EU Approval for Aspaveli in Rare Kidney Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApellis Pharmaceuticals' Partner Sobi Gains EU Approval for Aspaveli in Rare Kidney Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-16 21:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Apellis Pharmaceuticals (APLS) partner Sobi said Friday that the European Commission approved Aspaveli (pegcetacoplan) for adults and adolescents aged 12 to 17 with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN).</p><p>The therapy is used with a renin-angiotensin system (RAS) inhibitor unless it is not tolerated or contraindicated, Sobi said.</p><p>Aspaveli is a targeted C3/C3b inhibitor that regulates excessive complement activation, a key driver of these rare kidney diseases. C3G and IC-MPGN affect about 8,000 patients in Europe. Over half progress to kidney failure within five to 10 years, the company said.</p><p>Sobi and Apellis Pharmaceuticals hold global co-development rights, the release said.</p><p>Apellis shares were 1.7% higher in premarket trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7095","symbol_name":"多种金属与采矿","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2603199663","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603199663","pubTimestamp":1768568997,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Apellis Pharmaceuticals (APLS) partner Sobi said Friday that the European Commission approved Aspaveli (pegcetacoplan) for adults and adolescents aged 12 to 17 with C3 glomerulopathy (C3G) or primary ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7095":"多种金属与采矿","RAS.AU":"RAGUSA MINERALS LTD","BK7062":"资产管理与托管银行","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4156":"煤与消费用燃料","BK4588":"碎股","BK4505":"高瓴资本持仓","BK4585":"ETF&股票定投概念","APLS":"Apellis Pharmaceuticals Inc.","BK4139":"生物科技","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"Apellis Pharmaceuticals合作伙伴Sobi获得欧盟批准Aspaveli治疗罕见肾脏疾病","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APLS":1,"RAS.AU":1},"content_text":"Apellis Pharmaceuticals (APLS) partner Sobi said Friday that the European Commission approved Aspaveli (pegcetacoplan) for adults and adolescents aged 12 to 17 with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN).The therapy is used with a renin-angiotensin system (RAS) inhibitor unless it is not tolerated or contraindicated, Sobi said.Aspaveli is a targeted C3/C3b inhibitor that regulates excessive complement activation, a key driver of these rare kidney diseases. C3G and IC-MPGN affect about 8,000 patients in Europe. Over half progress to kidney failure within five to 10 years, the company said.Sobi and Apellis Pharmaceuticals hold global co-development rights, the release said.Apellis shares were 1.7% higher in premarket trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603199663","isCrawlerRequest":true}